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Abstract: Several recent, large-scale studies have provided valuable insights into patient 
 perspectives on postmenopausal vulvovaginal health. Symptoms of vulvovaginal atrophy, which 
include dryness, irritation, itching, dysuria, and dyspareunia, can adversely affect interpersonal 
relationships, quality of life, and sexual function. While approximately half of postmenopausal 
women report these symptoms, far fewer seek treatment, often because they are uninformed about 
hypoestrogenic postmenopausal vulvovaginal changes and the availability of safe,  effective, 
and well-tolerated treatments, particularly local vaginal estrogen therapy. Because women 
hesitate to seek help for symptoms, a proactive approach to conversations about vulvovaginal 
discomfort would improve diagnosis and treatment.
Keywords: health care professional, hypoactive sexual desire disorder, local vaginal estrogen 
therapy, quality of life, urinary tract infection, vulvovaginal atrophy
Introduction
The current life expectancy for American women is greater than 80 years and  continues 
to increase.1 At the time of the most recent census (2010), 53 million women aged 
50 years and older were living in the United States.2 Based on the average age of 
menopause in this population (50.5 years),3 and based on increasing life expectancy, 
most of these women may expect to live almost 40% of their lives after menopause. 
Therefore, while some may view menopause as an end-of-life event, it is in fact a 
midlife event.
Menopause is commonly associated with somatic symptoms, including hot flashes, 
night sweats, and fatigue, but women are less frequently aware of menopause-related 
vulvovaginal symptoms, including vulvovaginal dryness, recurrent urinary tract 
infections (UTIs), and dyspareunia.4–8 These symptoms are often associated with 
vulvovaginal atrophy (VVA), a condition that results from decreased estrogen in the 
vulvovaginal tissues.9 VVA can be diagnosed based on patient-reported symptoms and 
a physical examination.10,11
Symptomatic VVA, which can include an inflammatory reaction to atrophic changes 
known as atrophic vaginitis, can range in severity from bothersome to debilitating. 
First-line therapies recommended by the North American Menopause Society include 
vaginal moisturizers, continued sexual activity, and lubricants.12 Lubricants are tem-
porary in their action and are used immediately before and during sexual activity to 
decrease tissue irritation due to friction. In contrast, vaginal moisturizers are applied 
internally at regular intervals, are longer-acting, and can decrease vaginal dryness 
and lower vaginal pH.13,14 These agents do not restore normal vaginal anatomy and in 
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some patients may be insufficient or inadequate to resolve 
symptoms, because they do not treat their underlying cause: 
the hypoestrogenic vaginal environment. When symptoms 
persist after first-line therapies are employed, the two primary 
goals of management are to alleviate symptoms and to reverse 
atrophic anatomical changes. Vaginal local estrogen therapy 
(LET) is considered effective and well tolerated for the treat-
ment of moderate to severe symptomatic VVA;12 because 
of minimal systemic absorption of LET, local application is 
presently recommended over systemic estrogen therapy when 
VVA is the sole indication.12 The cellular and physiological 
changes that characterize VVA and the results of clinical 
trials investigating various treatments have been reviewed 
elsewhere.9,12,15
The aim of this review is to summarize findings from 
several recent survey-based studies that have provided 
profound insight into women’s experiences, opinions, and 
preferences regarding postmenopausal vulvovaginal health. 
Increased awareness of these patient perspectives among 
health care providers (HCPs) may help improve the diagnosis 
and treatment of VVA.
Methods
To locate recent and relevant surveys, a PubMed search was 
performed using the search term “postmenopausal women 
vaginal survey” and was restricted to English-language 
articles in the date range January 1, 2007, to April 1, 2012. 
Using the specified search criteria, 107 articles were located. 
After eliminating trials, studies that did not use surveys, 
studies that surveyed less than 1000 women, as well as 
studies that assessed data collected before 2002, a total 
of seven studies of women in North America and Europe 
remained (Table 1).5–8,16–18 Because the symptoms of VVA 
are most prevalent in women who have reached menopause, 
this review focuses on the postmenopausal population. 
 However, relevant data from perimenopausal women have 
been presented alongside data from postmenopausal women 
for comparison when both populations were addressed in a 
single survey. Though this review will emphasize insights 
learned from these seven key surveys, other recent surveys 
and key studies on vaginal atrophy that were either cited 
within the seven key survey publications and/or that were 
well known and widely accepted by experts in the field were 
also considered to complement, elaborate on, and amplify 
these important findings.
For the purposes of this review, VVA is a clinical diagno-
sis that is made based on an overall impression of symptoms 
and visual inspection of the vulvovaginal anatomy, with or 
without testing for confirmatory objective parameters such 
as pH or histology. Because all of the key studies considered 
in this review focused on self-reported experiences and per-
ceptions, it cannot necessarily be concluded that all of the 
women reporting symptoms of VVA would actually receive 
that diagnosis from a clinician.
Prevalence of vulvovaginal symptoms
In the seven key studies,5,7,8,16–18 vulvovaginal symptoms were 
described slightly differently, but the prevalence of symp-
toms was consistently about 50% (Table 1). VVA does not 
result in symptomatology such as discomfort or pain in all 
women. Gass et al11 found that more than two-thirds (69%) 
of women participating in the hormone therapy trials of the 
Women’s Health Initiative had physical evidence of VVA 
upon clinical examination at enrollment; only 10% of the same 
population, however, reported moderate to severe vaginal 
or genital  dryness. This study was unique in that it reported 
the prevalence of symptoms (ie, vaginal or genital dryness 
and irritation) and the investigator’s clinical impression of 
 atrophy. While many women exhibited signs of VVA (eg, loss 
of adipose tissue in external genitalia; thinning of pubic hair; 
atrophic, smooth, pale, or friable vagina; or friable cervix flush 
with the vaginal vault), not all were symptomatic.11
Vulvovaginal discomfort  
and its effects on women
Perceived severity of vulvovaginal 
symptoms
The discomfort associated with VVA can have a significant 
impact on health and overall quality of life (QoL). The VIVA 
(Vaginal Health: Insights, Views, and Attitudes) study,8 
which covered the broadest range of countries among the 
seven key surveys, reported the prevalence of individual 
symptoms among 1578 women with vaginal discomfort as 
follows: vaginal dryness, 83%; pain during intercourse, 42%; 
involuntary urination, 30%; soreness, 27%; itching, 26%; 
burning, 14%; and pain when touching the vagina, 11%. In 
the same study, most women with discomfort (62%) reported 
the severity of these symptoms as moderate or severe.  Santoro 
and Komi5 found vaginal dryness and sexual pain to be 
moderately or very bothersome in 42% of postmenopausal 
women who were not currently taking estrogen. Another 
study corroborated these findings, with 38% of postmeno-
pausal women reporting that their long-term vaginal dryness 
was a significant problem; these women rated the problem 5, 
6, or 7 on a Likert scale, with responses ranging from 1 (not 
a problem) to 7 (a very significant problem).19
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Effect of vulvovaginal discomfort on QoL
Vulvovaginal symptoms can also affect aspects of women’s 
lives beyond physical health. In the Women’s Voices in the 
Menopause study, about half (52%) of the respondents 
reported at least some degree of negative impact, including 
negative consequences for their sex life (40%), self-esteem 
(17%), marriage/relationship (13%), and social life (7%), 
although 38% reported that their discomfort had not affected 
them much.7 Many women also reported that vaginal discom-
fort made them “feel old” (32%) and gave them a lower QoL 
(14%).7 In another study, postmenopausal women agreed that 
long-term VVA symptoms adversely affected their sexual 
interest (59%), intimacy and relationship with a partner 
(55%), mood (42%), and self-esteem (34%).19 Additionally, a 
study by Cumming et al17 found that many women have tried 
to hide their vaginal dryness/discomfort from their partner 
(61% of peri- and postmenopausal women) and have made 
excuses to avoid intercourse because of their symptoms (42% 
of peri- and postmenopausal women). Respondents also 
reported that vaginal dryness/discomfort had affected their 
confidence (62% of peri- and postmenopausal women).17
Association of vvA with sexual dysfunction
Vulvovaginal symptoms may contribute to sexual problems 
and distress in postmenopausal women. Sexual desire has 
been found to decrease as women move through the meno-
pausal transition, partially as a result of declining testosterone 
levels.20,21 Levine et al18 found that postmenopausal sexually 
active women with sexual dysfunction, as defined using the 
Arizona Sexual Experiences Scale questionnaire, were nearly 
four times more likely to have symptoms of VVA than those 
without sexual dysfunction.22 Also, the co-occurrence of 
sexual dysfunction and its separate domains and VVA in this 
analysis population was high; for women with VVA, 40% 
also reported overall sexual dysfunction, 24% lack of desire, 
34% arousal difficulties, and 19% orgasm difficulties.22 These 
results are complemented by a separate large study of adult 
women (Prevalence of Female Sexual Problems Associ-
ated with Distress and Determinants of Treatment Seeking; 
 PRESIDE), which found that the prevalence of distressing 
sexual problems, as measured by the Female Sexual Distress 
Scale,23 peaked at 14.8% in middle-aged women aged 45 to 64 
years compared with women who were younger (aged 18–44 
years, 10.8%) or older (aged $65 years, 8.9%).24
In a second study by Cumming et al,16 more than one-
third (38%) of perimenopausal women and more than half 
(56%) of postmenopausal women reported dyspareunia 
secondary to vaginal dryness. Most of these women (78% 
and 87% in the perimenopausal and postmenopausal groups, 
respectively) considered dyspareunia to be a factor in their 
loss of libido.16 In another study, difficulty with lubrication 
was cited by 39% of women aged 57 to 85 years.25 The survey 
by Cumming et al16 also screened peri- and postmenopausal 
respondents for hypoactive sexual desire disorder (HSDD) 
using the Brief Profile of Female Sexual Function26 and found 
that respondents screening positive for HSDD overwhelm-
ingly felt that vaginal dryness was a factor in their reduced 
libido (90% of respondents).16 Likewise, a study of Italian 
women in surgical menopause found that vaginal dryness 
was significantly more reported by women with a decline of 
sexual desire than in those without a decline in desire (63.2% 
versus 30.2%; P = 0.001).27 In the Study of Women’s Health 
Across the Nation, women reporting vaginal dryness were 
more likely to report dyspareunia and lower arousal.20
Although many studies published over the last 30 years 
have shown that the frequency of sexual intercourse declines 
with age,28 a considerable proportion of postmenopausal 
women are sexually active.12,16 In examining the baseline 
characteristics of women participating in the hormone therapy 
trials of the Women’s Health Initiative, Gass et al11 found that 
about 61% of women aged 50 to 59 years were sexually active, 
followed by 45% of women aged 60 to 69 years and 28% of 
women aged 70 to 79 years. Nearly two-thirds (63%) of these 
women were satisfied with their sexual activity at the time of 
the survey, but of those dissatisfied, the majority (57%) would 
prefer more sexual activity. Women with clinically evident 
VVA were more likely to report sexual inactivity.11
Tolerating painful sex as a result of vvA
Many postmenopausal women continue to have sex, even 
though it is painful. In the REvealing Vaginal Effects At mid-
Life (REVEAL) study, one-quarter of women reported that 
they experienced dyspareunia at least sometimes.6 Of this 
dyspareunia subgroup, 72% engaged in sexual intercourse at 
least once a month and 34% at least once a week, despite the 
pain they were experiencing. Remarkably, 80% of the dyspare-
unia subgroup reported that they had learned to live with the 
vulvar and vaginal symptoms of menopause, such as dryness, 
as a normal part of getting older (compared with 51% of all 
respondents); 30% of women who experience dyspareunia 
said that the pain required interruption or discontinuance 
of sexual activity.6 Also in the REVEAL study, 56% of the 
dyspareunia subgroup said they were less sexually active as a 
result of the pain, while 6% said the pain prevented any attempt 
at sexual activity.6 The Study of  Women’s Health Across the 
Nation reported comparable frequency of intercourse between 
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premenopausal women and early perimenopausal women who 
reported more pain with intercourse.29 Therefore, it appears 
that while some women tolerate painful sex, others may reduce 
their frequency of sexual activity or discontinue sexual activity 
entirely. In each case, a clinical need is evident.
Urinary symptoms associated with vvA
VVA may also be associated with lower urinary tract symp-
toms, such as dysuria, urgency, frequency, nocturia, incon-
tinence, and recurrent UTIs. In any given year, about 8% of 
postmenopausal women may have an episode of UTI, and 
about 4% may have two or more episodes.30 Evidence sug-
gests that LET, but not systemic estrogen therapy, may pre-
vent urinary infections and improve symptoms,31,32 including 
incontinence, frequency, nocturia, and urgency.33 Although 
this review focuses primarily on the vulvovaginal symptoms 
of VVA, urinary symptoms also have a high prevalence in 
older women and may have negative effects on QoL and 
sexual activity.34 The PRESIDE study,35 for example, found 
a correlation between distressing sexual problems in women 
and urinary incontinence. Treating vulvovaginal symptoms 
with LET may address urinary complaints as well.36
Lack of understanding  
of vulvovaginal health
Many postmenopausal women are uninformed about midlife 
vulvovaginal health and its importance. In one study, 87% 
of postmenopausal women agreed with the statement, “My 
sexual health is important to me,”6 and in another, 84% of 
peri- and postmenopausal women answered “yes” to “Is an 
active sex life important?”16 So while most women value the 
importance of sex and sexual health, there is still a substantial 
minority that does not. In the REVEAL survey, only 9% of 
postmenopausal women disagreed with the statement, but 
this relatively small percentage potentially corresponds to 
4.5 million women (based on an estimated 50 million post-
menopausal women in the United States).6 These women 
likely have a variety of reasons for deprioritizing their sexual 
health, including the lack of a partner, other health concerns, 
or avoidance of sex because of vulvovaginal discomfort. 
However, women may benefit from receiving basic informa-
tion about the potential advantages of achieving or maintain-
ing sexual health in their peri- and postmenopausal years.
The VIVA study also investigated women’s knowledge of 
vulvovaginal health issues.8 Many women (42%) with vaginal 
discomfort realized that their condition was a symptom of 
menopause, although few (4%) were able to attribute “dry-
ness, itching, burning or soreness in the vagina, or pain during 
intercourse” to “vaginal atrophy.”8 More than one-third (37%) 
recognized vaginal discomfort as a chronic condition, but 45% 
did not know if it was chronic or acute; 18% thought it was 
an acute condition, despite the fact that 75% of women in the 
study had experienced symptoms for at least a year.8 In a sepa-
rate study,19 postmenopausal women with vaginal discomfort 
were asked if they would be more likely to seek treatment if 
they knew it was a treatable medical condition called “vagi-
nal atrophy” that could cause urogenital complications if left 
untreated. Nearly half of the women (44%) reported that they 
would be “very likely” to seek treatment.19 These responses 
highlight the importance of discussing the root cause of VVA 
(estrogen deficiency) with postmenopausal women.
Underdiagnosis and undertreatment 
of VVA
Although many women experience vulvovaginal symptoms 
with menopause, they often do not seek medical help.7,8,16 
Approximately one-third (32%) of the symptomatic respon-
dents in the VIVA study, for example, had never seen an HCP 
for the treatment of vaginal discomfort and 28% waited for 
more than 1 year,8 suggesting that VVA is an underdiagnosed 
and undertreated condition among postmenopausal women. 
Because none of the key surveys asked if a physician had 
formally diagnosed symptomatic patients with VVA, the true 
rate of diagnosis in these populations is not known and can-
not be directly compared with the proportion of women with 
symptoms and the proportion of women receiving treatment. 
There is, however, a clear discrepancy between the reported 
incidence of symptoms (see Table 1) and the reported inci-
dence of treatment, suggesting a need for improved diagnosis 
and management of VVA.
In the VIVA study, more women with vaginal discomfort 
used over-the-counter lubricating products, including gels 
and creams (49%), compared with prescription hormonal 
oral tablets and patches (22%), vaginal hormone creams 
(13%), vaginal hormone tablets (12%), and vaginal hormone 
rings (1%).8 Additionally, 22% of women with vaginal dis-
comfort had not tried any of the treatments mentioned in 
the survey; these included those just mentioned as well as 
vaginal hormone suppositories and mineral/vitamin supple-
ments (neither of which is approved in the United States for 
treating VVA). In Women’s Voices in the Menopause, 63% of 
women had never been prescribed any treatment for vaginal 
discomfort as a result of menopause, while 19% had been 
prescribed treatment in the past and only 17% were currently 
undergoing treatment.7 The number of women treated with 
prescription (or hormone-based) therapy for vulvovaginal 
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discomfort varied by country,7,8 with women in the United 
States, Canada, and the United Kingdom being treated less 
frequently than women in Finland and Sweden.7
In a UK-based survey, Cumming et al16 reported that only 
28% of perimenopausal women and 46% of postmenopausal 
women who were experiencing dyspareunia secondary 
to vaginal dryness and who believed this to be a factor in 
their loss of libido discussed the issue with their HCP. Of 
those who had a discussion, only 36% of perimenopausal 
respondents and 55% of postmenopausal respondents were 
on treatment. Among women with HSDD based on their 
answers to the Brief Profile of Female Sexual Function,26 
40% had discussed dryness with an HCP and of those only 
51% were on treatment.16 While the self-selecting nature of 
the sample may have introduced some bias, the results of this 
study exemplify how women who are candidates for therapy 
are missed at the diagnosis and treatment stages.16
Women who seek treatment for vulvovaginal discomfort 
are clearly bothered by their condition, and with treatment, 
many women report improvements in their everyday life, sex 
life, QoL, and their relationships.7 Women who have been diag-
nosed with VVA should be encouraged to begin managing their 
condition with appropriate treatment, following the guidelines 
of the North American Menopause Society, the International 
Menopause Society, and the Endocrine Society.12,37,38
Lack of awareness of treatment 
options for VVA
Many postmenopausal women are unaware of the recom-
mended treatment options, which may include LET, for vul-
vovaginal discomfort.7,8 In Women’s Voices in the Menopause, 
42% of women did not realize that local treatment was avail-
able for vaginal discomfort related to menopause.7 Awareness 
was country-specific, with those in the United States having 
the greatest lack of awareness (51%) and those in Finland 
having the least lack of awareness (10%). VIVA reported that 
most women (60%) were aware of over-the-counter options, 
such as lubricating gels and creams, although fewer were 
aware of prescription therapies.8 Among all categories of 
prescription therapies, women were most aware of hormonal 
oral tablets and patches (45%), which may be recommended 
by some HCPs when there is an additional indication for 
systemic therapy, such as the relief of moderate to severe 
vasomotor symptoms due to menopause or the prevention of 
 postmenopausal osteoporosis.39 Awareness of local hormone 
therapies, such as vaginal hormone creams (41%), vaginal 
hormone tablets (23%), and vaginal hormone rings (12%), 
was lower than awareness of oral tablets and patches.39 In 
a separate study, 67% of women said that they did not have 
enough information to make an informed choice about whether 
or not to start hormone therapy (therapy was not separated into 
local or systemic).17 These results suggest that there is a need 
to increase awareness of recommended treatment options for 
vulvovaginal discomfort among postmenopausal women.
Although about two-thirds of women who are prescribed 
hormonal treatment are likely to report positive effects,7 
many women are concerned about safety issues.8 The VIVA 
study investigated specific concerns about systemic and local 
hormone therapy separately.8 The primary concerns about 
systemic therapy, including both oral tablets and patches, 
were an increased risk of breast cancer (a concern reported 
by 53% of women) and an increased risk of developing a 
stroke or blood clot (a concern reported by 46% of women).8 
These concerns were also expressed regarding LET, although 
to a lesser extent: 27% of women were concerned about an 
increased risk of breast cancer, whereas 24% were concerned 
about an increased risk of developing a stroke or blood clot.8 
Strikingly, nearly half (46%) of the women surveyed in VIVA 
did not know what perceptions (positive or negative) to 
associate with LET, illustrating a need for patient  education. 
Women do not clearly understand the differences in the risks 
and benefits associated with local versus systemic therapy.12,39 
Interestingly, 30% of women asserted that they would not con-
sider LET, even if they knew it was effective and capable of 
maintaining normal hormone levels.8  However, 49% of women 
would be willing to try it and 20% were undecided,8 indicating 
that the majority of women, although they may be misinformed 
about LET, are receptive to additional information.
Sources of information about 
vulvovaginal health
When women in the VIVA study were asked what sources 
they had used or would use to understand vulvovaginal 
symptoms and/or treatment options, half cited their primary 
care doctor (50% overall; 49% United States) or their gyne-
cologist (46% overall; 56% United States).8 Approximately 
30% of women cited medical websites, women’s health 
websites, or menopause websites; 19% printed information 
in their doctor’s office; 15% magazines; and 14% friends. 
This information from non-HCP sources, such as the Internet 
and other women, may not be accurate or complete.
The PRESIDE study found that women who formally 
sought medical help for distressing sexual problems were 
 generally younger than women who sought no help or who only 
sought help anonymously from printed material,  television, 
radio, or Internet sources.35 Among women who formally 





International Journal of Women’s Health 2013:5
sought medical help, younger women (aged ,65 years) more 
often initiated a discussion with their HCP than older women 
(aged $65 years), and older women spoke with a primary 
care physician (54%) more often than with a gynecologist 
(30%).35 Less than half of women (44%) responding to the 
international VIVA study felt that there is enough information 
available about the symptoms and treatment of vulvovaginal 
discomfort.8 Finland was an outlier in this regard, with 76% 
of women reporting that enough information was available, 
compared with 37% to 42% in other countries.8
Unwillingness of patients and HCPs 
to discuss sexual health
Many postmenopausal women and their HCPs hesitate to 
discuss in an open conversation sexual health in general 
and vulvovaginal health, specifically; this presents a major 
challenge for diagnosing and managing VVA (see the section 
titled “Underdiagnosis and undertreatment of VVA”).
Patients’ main concerns
Only 38% of the women surveyed in REVEAL (a US-based 
study) had spoken to an HCP about their sexual health in the 
past year.6 Remarkably, some respondents (41%) had not talked 
to anyone about their sexual health in the past year, even with 
their partners or friends.6 Consistent with the data from PRE-
SIDE, this subset increased with age: 29% for women aged 
45 to 49 years, 35% for women aged 50 to 54 years, 42% for 
women aged 55 to 59 years, and 49% for women aged 60 to 65 
years.6 About half (47%) of the respondents in REVEAL agreed 
that it is still taboo in society for postmenopausal women to 
acknowledge experiencing vulvovaginal symptoms.6
When asked why sexual or vulvovaginal health topics are 
not discussed, women typically provide a reason that falls into 
one of three major categories: (1) embarrassment; (2) the belief 
that nothing can be done; and (3) the belief that the topic is not 
appropriate to discuss with an HCP (Table 2). Other reasons 
include thinking that the HCP is too busy,6 thinking that the 
HCP might be embarrassed,6 or wishing someone else (such as 
an HCP) would initiate the conversation.7 The degree to which 
these reasons are cited varies by country, with women in the 
United States reporting more embarrassment than women in 
Canada, Sweden, Finland, or the United Kingdom.7
Additionally, in a study of both men and women aged 57 
to 85 years, 38% of men had discussed sex with a physician 
since age 50 years, while only 22% of women had done so.25 
This discrepancy may result at least partially from societal 
constraints, which were explored in the REVEAL study.6 Most 
respondents (ie, postmenopausal women aged 55–65 years) 
agreed that society constrains the sexual expression of women 
their age more than that of men their age (75%), that society is 
more accepting of discussing men’s physical sexual problems 
than women’s (73%), and that society would prefer to believe 
that women their age do not have sex (53% of all respondents; 
60% of respondents aged 60–65 years).
Table 2 Self-reported reasons for not discussing vulvovaginal health or dyspareunia with HCP
Reason Language used in survey Rate among respondents Reference
Embarrassment “It makes me uncomfortable/ 
embarrassed.”
47% of those with vaginal discomfort Women’s voices 
in the Menopause7
“I am embarrassed.” 39% of those who have not talked  
to an HCP about dyspareunia
REvEAL6
Embarrassed about sexual  
problems23 
59% of women who did not seek help  
were at least moderately embarrassed
PRESIDE35
Belief that nothing  
can be done
“It’s just part of growing older.” 39% of those with vaginal discomfort Women’s voices 
in the Menopause7
“There is nothing than can be  
done medically to help me.” 
26% of those who have not talked  
to an HCP about dyspareunia
REvEAL6
Belief that it is an  
inappropriate topic  
to discuss with an HCP
“I do not think other people want  
to hear about my vaginal problems.”
59% of those with vaginal discomfort Women’s voices 
in the Menopause7
“It is private and does not  
concern others.”
41% of those with vaginal discomfort Women’s voices 
in the Menopause7
“It is not an appropriate discussion  
to have with an HCP.”
23% of those who have not talked  
to an HCP about dyspareunia
REvEAL6
Abbreviations: HCP, health care provider; REvEAL, Revealing vaginal Effects at Midlife study; PRESIDE, Prevalence of Female Sexual Problems Associ ated with Distress 
and Determinants of Treatment Seeking study.
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Patients waiting to report symptoms
In the VIVA study, nearly half (47%) of women who even-
tually saw an HCP about their symptoms waited more than 
6 months, whereas 28% waited more than 1 year and 15% 
waited more than 2 years.8 Similarly, the Women’s Voices 
in the Menopause study found that 25% of women (32% 
of women in the United States) who had been prescribed 
treatment for their vulvovaginal symptoms had experienced 
symptoms for at least 1 year, while 5% to 11% of women 
(depending on country, 11% in the United States) had waited 
at least 3 years.7 Some of these women may have simply 
been waiting for an HCP to initiate a conversation about 
vulvovaginal symptoms or sexual health.7 Others may believe 
that such changes would resolve or that they are a normal 
part of aging.38
Patient preferences with terminology
When discussing vulvovaginal symptoms and VVA with 
patients, HCPs should be mindful that women are generally 
not familiar or comfortable with the term “vaginal atrophy.” 
In the VIVA study, about one-third (32%) of women felt 
that the term “vaginal dryness” was appropriate to describe 
“dryness, itching, burning, or soreness in the vagina or pain 
during intercourse,” whereas only 11% preferred the term 
“vaginal discomfort.”8 Very few women considered the terms 
“poor vaginal health” (2%), “vaginal dysfunction” (2%), or 
“vaginal atrophy” (2%) to be suitable.8 These preferences 
may be helpful to keep in mind when broaching the subject 
of vulvovaginal health.
HCP perspective on discussing 
vulvovaginal health and role in improving 
diagnosis and treatment
Few surveys investigate vulvovaginal health from the per-
spective of the HCP. In the HCP portion of the REVEAL 
study, the survey responses of 602 HCPs (200 primary care 
physicians, 202 obstetrician/gynecologists, and 200 nurse 
practitioners) were compiled.6 Ninety-five percent of HCPs 
thought that treating a woman’s vulvovaginal health was 
important to her overall physical health, and most reported 
that they discussed dyspareunia at least sometimes (36% 
“often;” 49% “sometimes”).6 However, 44% of women who 
experienced dyspareunia and spoke to an HCP said that they 
initiated the conversation themselves; only 10% said that their 
HCP initiated the conversation.6 Multiple factors may influ-
ence the degree to which HCPs discuss sexual topics with 
patients, including lack of time, lack of training/experience, 
fear of embarrassing themselves or their patients, or even 
personal religious beliefs.40
Discussion and practice 
recommendations
The surveys described in this review reveal a large population 
of menopausal women suffering in silence with VVA-related 
symptoms that are significantly impacting their QoL, includ-
ing their sexual relationships and self-esteem. In addition, 
the surveys indicate that many of these women do not dis-
cuss their symptoms and that many lack information about 
the possibility of effective treatment. Further research is 
needed to examine the impact of VVA on partners of meno-
pausal women and to explore outcomes, including sexual 
 functioning/satisfaction and QoL, for women whose VVA 
has been treated. Future studies should also evaluate regional 
differences in women’s expectations and experiences, such 
as those that are related to their treatment options and the 
health care system. The improved recognition, diagnosis, 
and treatment of VVA depend on increased communication 
between patients and HCPs regarding midlife vulvovaginal 
changes and effective, well tolerated treatment options for 
menopause-related vulvovaginal discomfort.
With improved health care, women are living longer in 
the postmenopausal hypoestrogenic state. HCPs should com-
municate with their patients about the potential manifesta-
tions and management of VVA so that symptomatic women 
may seek appropriate treatment rather than accepting pain 
and discomfort as a natural consequence of aging. Because 
many postmenopausal women, especially older women, 
may no longer see an obstetrician/gynecologist regularly, 
it is imperative to educate all clinicians, including those 
in internal medicine, family physicians, and other primary 
care providers, about the full impact of VVA and the need 
to proactively and empathically address this condition. For 
example, a diagnosis of VVA should be considered for 
postmenopausal women who present to their primary care 
physician with a history of recurrent UTIs or worsening 
symptoms of urinary urgency.
HCPs may improve the diagnosis and treatment of VVA 
by initiating conversations at routine examinations to increase 
patient awareness and understanding of midlife vulvovaginal 
changes and treatment options. Studies of the patient-HCP 
dialogue have indicated that, in the case of potentially sensi-
tive issues of sexuality, patients may not offer complaints 
spontaneously, but will reveal them after being asked.41 
Patients often prefer screening “ubiquity” statements that 
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address the concerns of their group.21,42 An example of such 
a statement would be, “Many women find after menopause 
that they experience vaginal dryness, irritation, or pain during 
sex. Have you experienced anything like that?” The HCP’s 
use of focused questions that model the level of explicitness 
desired from the patient can elicit more specific information. 
HCPs can then use open-ended questions to follow up posi-
tive responses. In addition HCPs may schedule a follow-up 
visit if additional time is required to address sexual issues.21 
All HCPs who regularly see postmenopausal women have 
a responsibility to their patients to routinely ask about 
symptoms of VVA and to perform periodic clinical exami-
nations to detect VVA (Table 3).43–45 In addition, providing 
peri- and postmenopausal patients with at least one or two 
information leads, such as pamphlets or reliable websites, 
may motivate women to become better-informed advocates 
of their own vulvovaginal health and to then seek treatment, 
if necessary.
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Table 3 Clinical findings indicating vulvovaginal atrophy
•  Pale, smooth, shiny, or friable/unrugated epithelium
•  Loss of elasticity of genital skin
•  vulvar dermatoses, lesions, or erythema
•  Urethral caruncle or polyps
•  Low serum estrogen levels
•  Elevated vaginal pH $ 5.5
•  Thinning of endometrial uterine lining
•  Change in cytology of vaginal cells to primarily parabasal  
and intermediate cells
Note: Data from43–45.
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